Article

Acucela receives 'Emerging Leader' award

Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards

Seattle-Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards.

Acucela is a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases.

Now in its second year, the Japan-U.S. Innovation Awards program is sponsored by the Japan Society of Northern California in collaboration with the Stanford University U.S.-Asia Technology Management Center. The awards are designed to recognize the synergy between Japan and the United States by honoring outstanding companies from both countries that have achieved highly noteworthy innovation in their business or technology.

The Emerging Leaders award highlights two companies-one from Japan and one from the United States-that are young, small, dynamic, growing, entrepreneurial, and have a credible footprint in both Japan and the United States.

“It is an honor to accept this award on behalf of Acucela, and a testament to the important work our entire team contributes every day to continue the fight against blinding eye diseases,” said Ryo Kubota, MD, PhD, Acucela’s chairman, president, and chief executive officer.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.